LPATH

Lpath, Inc. is the category leader in the discovery and development of monoclonal antibodies that target (neutralize) bioactive lipids. The study of lipids (called lipidomics) is an emerging field of research that has already identified dozens of bioactive lipids that contribute to disease, with the promise of hundreds more as funding in the area continues to accelerate. Once a disease-causing lipid is identified, however, the challenge becomes one of generating a compound that neutralizes the relevant bioactive lipid. With its ImmuneY2:tm: platform technology and robust patent estate, Lpath is uniquely positioned to meet such challenges and exploit these opportunities.